Clinical Trials

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03907475 2026-03-18

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04031677 2026-03-18

STRASS2

Phase 3 Recruiting

250 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma

NCT04038619 2026-03-18

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

BreastDermatologicGynecologicThoracic

40 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

NCT04065399 2026-03-18

AUGMENT-101

LymphoidOther hematologic neoplasm

447 enrolled 2 FDA

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04071236 2026-03-18

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

90 enrolled

Lymphatic Metastasis, Prostatic Neoplasms

NCT04077099 2026-03-18

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

231 enrolled

Thoracic

Deafness, Autosomal Recessive 39, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04172532 2026-03-18

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

92 enrolled

Pancreatic Neoplasms

NCT04256317 2026-03-18

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Classical hematologyMyeloidOther hematologic neoplasm

316 enrolled

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04314401 2026-03-18

National Cancer Institute "Cancer Moonshot Biobank"

Recruiting

1,600 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04375384 2026-03-18

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

38 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04402788 2026-03-18

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

138 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT04443088 2026-03-18

KEYNOTE-E12

Other hematologic neoplasm

78 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04546945 2026-03-18

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Recruiting

38 enrolled

Hematologic Neoplasms

NCT04569591 2026-03-18

DDAVP for Pituitary Adenoma

Phase NA Recruiting

22 enrolled

Endocrine

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

806 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04633239 2026-03-18

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase EARLY_PHASE1 Recruiting

42 enrolled

Gynecologic

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT04655404 2026-03-18

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

15 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

GastrointestinalGynecologic

442 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

NCT04671667 2026-03-18

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

188 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04674267 2026-03-18

REACH

Phase NA Recruiting

257 enrolled

Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT04678648 2026-03-18

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

CNSGastrointestinalThoracic

134 enrolled

Colonic Neoplasms, Glioblastoma, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT04704661 2026-03-18

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

BreastGastrointestinalGynecologicHead & NeckSarcoma

51 enrolled

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

92 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04847453 2026-03-18

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

24 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04895839 2026-03-18

PC-PEP

Phase NA Recruiting

2,130 enrolled

Psychological Well-Being, Prostatic Neoplasms

NCT04929028 2026-03-18

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

40 enrolled

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT04939051 2026-03-18

Obeticholic Acid for Prevention in Barrett's Esophagus

30 enrolled

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT04981509 2026-03-18

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

65 enrolled

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05006716 2026-03-18

CaDAnCe-101

LymphoidOther hematologic neoplasm

614 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05007379 2026-03-18

CARMA

Recruiting

100 enrolled

Breast

Breast Neoplasms

NCT05019716 2026-03-18

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

36 enrolled

Advanced NUT Carcinoma

NCT05053971 2026-03-18

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

49 enrolled

Pancreatic Neoplasms

NCT05092451 2026-03-18

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances